Navigation Links
Rigel to Present at JMP Securities Research Conference
Date:5/13/2009

SOUTH SAN FRANCISCO, Calif., May 13 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the 8th Annual JMP Securities Research Conference in San Francisco on Wednesday, May 20th at 2:00 p.m. PT.

To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

    Contact: Ryan Maynard
    Phone: 650.624.1284
    Email: invrel@rigel.com


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Rigel to Present at Barclays Capital Healthcare Conference
2. Rigel Announces Fourth Quarter and Year End 2008 Financial Results
3. Rigel to Present at BIO CEO & Investor Conference
4. Rigel to Host Conference Call on February 3, 2009
5. Rigel to Present at Keystone Symposia Conference
6. Phase 2 Results of Rigels R788 Show Clinical Benefit in Diffuse Large B-Cell Lymphoma and CLL
7. Rigel to Present at the Piper Jaffray Annual Health Care Conference
8. Rigel to Present at the Oppenheimer 19th Annual Healthcare Conference
9. Rigel to Webcast Investor Update on October 27, 2008
10. QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc.
11. Rigel to Present at Collins Stewart Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... Young Asset Protection, an insurance ... throughout the greater Pittsburgh metropolitan region, is joining forces with the local chapter ... differently-abled children. , Variety the Children’s Charity is a national organization dedicated to ...
(Date:4/21/2017)... ... April 21, 2017 , ... The Hong Kong Polytechnic University (PolyU) launched ... among higher education institutions in Hong Kong to support teaching, learning and research. It ... and quantity of facilities in Hong Kong. , With an area of 620 ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... held the much anticipated Regional Primary Care Spring Symposium on April 1, 2017 ... local medical community, offering physicians and healthcare providers an opportunity to learn about ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Westside Dental ... personalized dental care since 1985. After thirty-two years, Dr. Latner has become one of ... help my numerous clients over the years with all their dental needs,” said Dr. ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... reveals good news for older shoulder replacement patients; post-operative recovery just might be ... two groups of patients presenting with osteoarthritis following surgery: 262 patients under 65 ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... the "Global Biosimilar Pipeline and Market Prospects: Addressing ... report to their offering. ... "Global Biosimilar Pipeline and Market ... by Design" provides an in-depth assessment of the current ...
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
(Date:4/19/2017)... Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that it ... 2017 at the Sheraton Hotel in Toronto, Ontario ... the Company is scheduled to present on Tuesday, May 2 at ... Chairman of the Board, Tony Holler will also attend ... For more details ...
Breaking Medicine Technology: